Aduro BioTech, Inc. (ADRO)


Stock Price Forecast

Oct. 5, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Aduro BioTech, Inc. chart...

About the Company

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.

Sector

Health Technology

Industry

Biotechnology

Employees

96

CEO

Stephen T. Isaacs

Exchange

NASDAQ

Website

http://www.aduro.com

$3B

Total Revenue

96

Employees

$502B

Market Capitalization

1459.50

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ADRO News

Aduro Biotech, Merck Team on Cancer Drug Trial

6y ago, source: TheStreet.com

Aduro Biotech and Merck will team on two separate trials featuring Aduro's CRS-207 and Merck's Keytruda to explore treatments for mesothelioma and gastric cancer. Aduro Biotech and Merck will team ...

Aduro Biotech Pancreatic Cancer Immunotherapy Fails Mid-Stage Study

7y ago, source: TheStreet.com

A type of common bacteria re-engineered by Aduro Biotech to engage the immune system to kill pancreatic cancer failed a mid-stage study, the company announced Monday. A type of common bacteria re ...

Lobbying Firm Profile: Innovative Federal Strategies

1mon ago, source: OpenSecrets.org

Aduro BioTech Innovative Federal Strategies FIRST QUARTER (NO ACTIVITY ... CA Innovative Federal Strategies THIRD QUARTER REPORT $10,000 Cray Inc Innovative Federal Strategies FIRST QUARTER REPORT $30 ...

Aduro Clean Technologies Inc Ordinary Shares ACTHF

7d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Biotech Stock News Bite - Avalo Therapeutics, Inc. (NASDAQ: AVTX) Makes NASDAQ Top Gainers List on News it acquired Phase 2-ready anti-IL-1β mAb

2h ago, source: Investor ideas

Investorideas.com ( Biotech Stock News Bites - Avalo Therapeutics, Inc. (Nasdaq: AVTX) blew other stocks away making the NASDAQ top percentage gainer in today's session, currently trading at $ 22.58, ...

3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List

on MSN ago, source:

Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year.More From ...

Fortress Biotech, Inc. (FBIO)

1y ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Noile-Immune Biotech Inc 4893

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

MBRX Moleculin Biotech, Inc.

6d ago, source: Seeking Alpha

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin ...

Can Krystal Biotech, Inc. (KRYS) Run Higher on Rising Earnings Estimates?

20d ago, source: Yahoo Finance

Krystal Biotech, Inc. (KRYS) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might ...

Can Krystal Biotech, Inc. (KRYS) Run Higher on Rising Earnings Estimates?

20d ago, source: Zacks.com on MSN

Over the last 30 days, two estimates have moved higher for Krystal Biotech, Inc. compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 180.68%. Current-Year ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...